Trial Profile
Immunogenicity Study of DTaP-IPV-Hep B-PRP-T Combined Vaccine in Comparison to Infanrix Hexa, at 2-4-6 Months of Age in Healthy Peruvian Infants.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Influenza B virus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors Sanofi; Sanofi Pasteur
- 21 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2009 New trial record